论文部分内容阅读
目的:探究稳心颗粒联合瑞舒伐他汀治疗老年冠心病患者临床疗效及安全性。方法:选取42例本院收治的老年冠心病患者,按照随机数字表法分为实验组和对照组。对照组21例,予美托洛尔片25 mg,起始量12.5 mg/日口服,日2次,如无首剂反应将剂量加至25 mg/日,日2次,瑞舒伐他汀片10 mg口服,日1次;实验组21例予稳心颗粒9g温开水冲服,日3次,瑞舒伐他汀10 mg口服,日1次。治疗28天后,观察和比较两组患者治疗前后CK-MB、肝功能及临床疗效。结果:治疗后,实验组有效率(95.2%)显著高于对照组(81.0%),差异有统计学意义(P<0.05)。与治疗前相比,两组患者治疗后谷草转氨酶(AST)、谷丙转氨酶(ALT)、总胆红素(TBil)、胱抑素C水平、左室射血分数(LVEF)均升高(P<0.05),总胆固醇(TC)、低密度脂蛋白(LDL-C)水平及磷酸肌酸激酶同工酶(CK-MB)水平均降低(P<0.05)。与对照组相比,实验组LVEF及胱抑素C水平较高(P<0.05)。结论:稳心颗粒联合瑞舒伐他汀治疗老年冠心病患者可有效降低血脂,缓解患者胸闷、心悸等症状,对肝脏及肾脏功能损伤小,且安全性高。
Objective: To investigate the clinical efficacy and safety of Wenxin granule combined with rosuvastatin in elderly patients with coronary heart disease. Methods: Forty-two elderly patients with coronary heart disease admitted to our hospital were divided into experimental group and control group according to random number table. In the control group, 21 cases were treated with metoprolol 25 mg, initial dose 12.5 mg / day orally and twice daily. If the first dose was not added, the dosage was increased to 25 mg / day and twice daily. Rosuvastatin tablets 10 mg orally, day 1; 21 cases of experimental group to Wenxin particles 9g warm boiled water, 3 times a day, rosuvastatin 10 mg orally, day 1 time. After 28 days of treatment, CK-MB, liver function and clinical efficacy were observed and compared before and after treatment. Results: After treatment, the effective rate of the experimental group (95.2%) was significantly higher than that of the control group (81.0%), the difference was statistically significant (P <0.05). The levels of AST, ALT, TBil, Cystatin C and LVEF in both groups were significantly higher than those before treatment (P <0.05) (P <0.05). The levels of total cholesterol (TC), low density lipoprotein (LDL-C) and creatine phosphokinase (CK-MB) were decreased (P <0.05). Compared with the control group, the levels of LVEF and cystatin C were higher in experimental group (P <0.05). Conclusion: Wenshen granule combined with rosuvastatin can effectively reduce blood fat, alleviate the symptoms of chest tightness and palpitations in patients with senile coronary heart disease, have less damage to liver and kidney, and have high safety.